This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $798,958 to Northwestern University to conduct research on the mechanisms driving chronic lung allograft dysfunction (CLAD) after lung transplantation. The research aims to determine if early primary graft dysfunction (PGD) following transplantation induces chronic activation of the integrated stress response (ISR) in the airway...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $799,354 to Northwestern University to conduct research on the role of necroptosis, a form of programmed cell death, in primary graft dysfunction (PGD) following lung transplantation. The research aims to comprehensively understand the necroptotic pathways in both the donor and recipient lungs that contribute to PGD, a severe...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $616,000.00 to Northwestern University over a 5-year period beginning September 1, 2024. The award supports research to determine the mechanisms by which mitochondrial dysfunction and metabolic changes impact alveolar epithelial cell differentiation and the development of lung fibrosis. The project aims to use...
The federal Project Grant award R01HL171164, totaling $786,147.00, was issued by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). This grant supports research to investigate the mechanistic links between hypoxia (oxygen deficiency), aberrant lactate generation and shuttling, and their direct impact on promoting pro-fibrotic phenotypes in lung fibroblasts, which are critical to the pathobiology of progressive fibrotic lung...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,183,648.00 to Northwestern University to conduct research on the role of macrophage phagocytes in cardiac inflammation and disease pathophysiology. The project aims to investigate key immunometabolic signaling pathways that contribute to chronic cardiac inflammation, particularly in the context of heart failure and risk factors...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,063,324 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Tulane University. The grant, awarded on June 5, 2025, will support research to investigate the metabolic requirements and survival mechanisms of lung and nasal tissue-resident memory CD4+ T cells, and their interactions with lung fibroblasts, to enhance the understanding of pulmonary host defenses against respiratory pathogens. The research...
This $600,761 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the role of Natural-Killer Group 2, Member D (NKG2D) signaling in lung inflammation and the development of bronchopulmonary dysplasia (BPD) in preterm infants. The goal is to map the cell fate and define the role of NKG2D+ lymphocytes, as well as determine the cellular sources and immunogenicity of NKG2D...
This federal Project Grant award, totaling $583,233.00 and issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to investigate the role of circulating osteopontin and innate immune cell CD44 in remote lung inflammation following acute kidney injury. The primary objectives are to: 1) determine which osteopontin domains and thrombin cleavage are required to induce remote lung inflammation, 2)...
The University of Illinois received a $760,759 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant, with a period of performance from May 2025 to February 2029, will fund research to characterize the anti-inflammatory role of the CX3CR1+ conventional dendritic cell type 2 (CDC2) subset in regulating allergic lung inflammation associated with asthma. The researchers aim to determine how this...
This federal Project Grant award, valued at $313,632.00 and provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a 5-year research project led by Dr. Joseph Cooley at National Jewish Health in Denver, Colorado. The project aims to investigate how interleukin-6 (IL-6) promotes resistance to apoptosis (programmed cell death) in lung fibroblasts, and to explore therapeutic strategies targeting the IL-6-BCL-2...